Quanta Dialysis Technologies | Top Medtech Startup in UK 2022

MedTech Outlook Magazine

Quanta Dialysis Technologies
Transforming Kidney Treatment with Convenient Home Haemodialysis

Dr Paul Komenda, Chief Medical Officer, Quanta Dialysis TechnologiesDr Paul Komenda, Chief Medical Officer
Globally, most kidney failure patients have to endure life-saving, yet antiquated dialysis care at healthcare facilities and clinics. Dialysis devices used at most facilities require specialized healthcare professionals to manage and operate them, making the process even more complex. Since patients must visit clinics and undergo four-hour-long treatment at least three times a week, this old-fashioned delivery model affects their day-to-day lives and mental health.

With the vision to make dialysis accessible to every patient in every setting, Quanta Dialysis Technologies developed an intelligent haemodialysis device for improved patient convenience. The company is transforming kidney care with its proprietary SC+ haemodialysis system that is taking the UK’s nephrology arena by storm.

The SC+ haemodialysis system is an end-to-end solution that furnishes performance levels equivalent to conventional larger dialysis machines while providing the clinical flexibility to customise care dependent on individual patient need. The compact system, which was developed with the user in mind, has a user-friendly interface and a highly intuitive and ergonomic design, functioning as an ingenious modular device that delivers high-grade clinical outcomes. Quanta has embedded the device with a broad range of user accessibility across various settings, simplifying dialysis for medical professionals at their hospitals and allowing patients the freedom to conduct dialysis in their homes.

“We combine the convenience of a small device with the power of a large complex haemodialysis system. With dialysate flow rates of 300 mL/min for longer, slower therapies such as SLED and 500 mL/min to meet the standard of care, the SC+ system offers flexible prescription therapy, giving greater clinical versatility to our product,” says Dr Paul Komenda, Chief Medical Officer of Quanta.
Quanta’s team of seasoned experts pooled their longstanding experience to miniaturise complex fluidic circuitry onto a proprietary disposable cartridge that accurately mixes, generates, and pumps dialysate fluid; eliminating the requirement for descaling and disinfection after each therapy session. These innovative functionalities diminish the risk of cross-contamination and infection, bolstering overall patient safety. To ensure that the dialysis process is streamlined and operationally efficient, Quanta integrates SC+ with its cloud-based digital health platform.

The platform empowers healthcare professionals to manage treatment data seamlessly, monitor device performance remotely, and deliver 24/7 customer support. The SC+ collects and transmits specific device and treatment data to the secure Quanta Digital Cloud. These parameters are associated to a patient treatment record which empowers both the patient and clinician to review previous treatments session to gain insights into how a patient is dialyzing. To ensure patient privacy, SC+ and the Quanta Digital Platform are designed with strict cybersecurity. Apart from the revolutionary device that Quanta has developed, what differentiates the company from others is the level of support and care it renders to its users.

We combine the convenience of a small device with the power of a large complex haemodialysis system

Quanta believes that the only way to truly revolutionise kidney care and reduce the burden for patients is to break down the barriers of home haemodialysis and transform antiquated treatment models by making dialysis accessible to every patient in every setting. Quanta’s SC+ haemodialysis system also renders notable economic value propositions that make it an ideal choice for patients and their providers. A recent study shows that the SC+ systems can deliver a up to a 26 percent cost reduction compared to traditional in-centre haemodialysis. This study demonstrates how patients in the UK using the SC+ system at their homes significantly reduced costs, making their treatment less burdensome on their finances.1

On 13 July 2022, Quanta received the MacRobert Award, the UK’s longest running and most prestigious award for UK engineering innovation, recognising the company’s triumph in developing a ground-breaking product that is truly novel in the global nephrology space and substantiates Quanta’s reputation as a user- and patient-centric brand.

References: 1Ferguson T., et al. Cost of the quanta SC+ hemodialysis system for self-care in the United Kingdom. Hemodialysis International. 09 Jan 2022;1-8.

Top 5 Medtech Startups in UK - 2022

Company
Quanta Dialysis Technologies

Management
Dr Paul Komenda, Chief Medical Officer

Description
Quanta Dialysis Technologies offers an end-to-end hemodialysis system that delivers performance levels equivalent to conventional larger machines while ensuring remarkable levels of flexibility, enabling healthcare professionals to ensure efficient and cost-effective delivery of hemodialysis.

Quanta Dialysis Technologies News

US FDA expands Quanta Dialysis System indication to include CRRT modalities

The FDA approval expands the indication for Quanta Dialysis System to include two new continuous renal replacement therapy (CRRT) modalities, continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF)
UK-based medical technology company Quanta Dialysis Technologies has received the US Food and Drug Administration (FDA) 510(k) approval for the expanded use of its Quanta Dialysis System.
The compact haemodialysis device was originally designed to serve people with end-stage kidney disease (ESKD) who receive treatment with dialysis or a kidney transplant.
The FDA approval expands the indication for Quanta Dialysis System to include two new modalities of continuous renal replacement therapy (CRRT).
It allows the device to be used for continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF) procedures.
With the expanded approval, Quanta becomes the only FDA-approved dialysis device to offer both intermittent haemodialysis (IHD) and sustained low-efficiency dialysis (SLED).
Quanta CEO Alejandro Galindo said: “This clearance is a true game-changer for acute care settings. Hospitals are often constrained with limited space and nursing staff.
“The Quanta Dialysis System with TKT software provides an all-in-one solution for hospitals with an intensive care unit (ICU) looking to reduce their device footprint, maximise their operational efficiencies, reduce the burden on nurses and substantially lower consumables expenses.”
According to the company, the haemolysis device features the latest Trinal Kidney Therapy (TKT) software that provides a treatment solution for critical acute kidney injury (AKI) patients.
The system supports dialysate flow rates from 50 to 500mL/min and treatment times up to 24 hours of continuous delivery.
Also, Quanta said that CRRT provides a slower and gentler alternative to conventional dialysis.
Unlike traditional haemodialysis, which occurs over a four-hour period, continuous dialysis runs 24 hours a day to provide better real-time management of volume and biochemistry for patients.
The company plans to commercialise its haemodialysis system with TKT software this year.
Quanta chief medical officer Paul Komenda said: “Critically ill patients that are hemodynamically unstable, such as those with severe AKI, are more challenging to manage in the ICU balancing volume status, inotropic support and ventilation requirements.
“Because of its slower rate of fluid removal, CRRT may cause less stress for the patient and enable more real-time decision-making for clinical teams on a minute-to-minute basis.
“However, once the hemodynamic status of the patient has improved, a transition to IHD or SLED may be the best option. A device that can perform all three modalities in one is ideal.”

Quanta™ Receives FDA 510(k) Clearance for Expanded Indication of Continuous Renal Replacement Therapies

Quanta Dialysis System becomes first-in-class to perform three standard-of-care dialysis modalities in one device
BEVERLY - Quanta Dialysis Technologies®, a medical technology company committed to making kidney care more accessible, today announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication of the Quanta Dialysis System, a compact and easy-to-use hemodialysis device, for two modalities of continuous renal replacement therapy (CRRT): continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF). Under the new 510(k), the Quanta Dialysis System is the only dialysis device FDA-cleared to provide intermittent hemodialysis (IHD), sustained low efficiency dialysis (SLED) or bagless CRRT which creates dialysate on demand – all in a single machine.
The primary intent behind the creation of the Quanta Dialysis System was to cater to the needs of the global population exceeding two million, who suffer from end-stage kidney disease (ESKD) and undergo treatments like dialysis or kidney transplantation. The recent incorporation of the Trinal Kidney Therapy™ (TKT) software further extends its capabilities to offer a treatment remedy for individuals critically afflicted by acute kidney injury (AKI) and necessitating dialysis. The system encompasses dialysate flow rates ranging from 50 to 500 mL/min, enabling treatment durations of up to 24 hours for uninterrupted administration.
"This clearance is a true game-changer for acute care settings," said Quanta Chief Executive Officer, Alejandro Galindo. "Hospitals are often constrained with limited space and nursing staff. The Quanta Dialysis System with TKT software provides an all-in-one solution for hospitals with an intensive care unit (ICU) looking to reduce their device footprint, maximize their operational efficiencies, reduce burden on nurses and substantially lower consumables expenses."
The mortality rate among intensive care unit (ICU) patients suffering from severe acute kidney injury (AKI) necessitating dialysis has been documented to surpass 50%. These patients often rely on intravenous life support to sustain a minimal blood pressure. Continuous Renal Replacement Therapy (CRRT) presents a more gradual and delicate substitute to conventional dialysis. Unlike the traditional four-hour hemodialysis sessions, CRRT operates continuously for 24 hours daily, allowing improved real-time monitoring and adjustment of patient volume and biochemical levels.
"Critically ill patients that are hemodynamically unstable, such as those with severe AKI, are more challenging to manage in the ICU balancing volume status, inotropic support and ventilation requirements. Because of its slower rate of fluid removal, CRRT may cause less stress for the patient and enable more real-time decision making for clinical teams on a minute-to-minute basis," said Quanta Chief Medical Officer, Dr. Paul Komenda, MHA, FRCPC, FASN. "However, once the hemodynamic status of the patient has improved, a transition to IHD or SLED may be the best option. A device than can perform all three modalities in one is ideal."
Quanta is ready to commercialize the Quanta Dialysis System with TKT software and expects to officially launch the product at the 2023 American Society of Nephrology Annual Meeting.